EW Edwards Lifesciences Corp

Price (delayed)

$88.18

Market cap

$50.77B

P/E Ratio

46.66

Dividend/share

N/A

EPS

$1.89

Enterprise value

$49.03B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 67

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, ...

Highlights
EW's quick ratio is up by 17% since the previous quarter
EW's revenue is up by 14% year-on-year and by 3.9% since the previous quarter
The net income has plunged by 74% YoY but it has grown by 2.1% from the previous quarter
The company's EPS has shrunk by 73% YoY but it rose by 2.7% QoQ
The price to earnings (P/E) is 37% higher than the last 4 quarters average of 33.2 and 36% higher than the 5-year quarterly average of 33.5
EW's gross margin is down by 2% year-on-year

Key stats

What are the main financial stats of EW

EW stock price

How has the Edwards Lifesciences stock price performed over time
Intraday
2.45%
1 week
6.19%
1 month
-6.56%
1 year
11.16%
YTD
3.44%
QTD
-2.52%

Financial performance

How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$6.3B
Gross profit
$4.91B
Operating income
$1.06B
Net income
$1.1B
Gross margin
77.9%
Net margin
17.4%
The net margin has plunged by 77% YoY
The net income has plunged by 74% YoY but it has grown by 2.1% from the previous quarter
The company's operating margin fell by 34% YoY and by 7% QoQ
The operating income has contracted by 25% YoY and by 3.7% from the previous quarter

Price vs fundamentals

How does EW's price correlate with its fundamentals

Growth

What is Edwards Lifesciences's growth rate over time

Valuation

What is Edwards Lifesciences stock price valuation
P/E
46.66
P/B
4.95
P/S
8.1
EV/EBIT
36.55
EV/EBITDA
32.07
EV/Sales
7.78
The company's EPS has shrunk by 73% YoY but it rose by 2.7% QoQ
The price to earnings (P/E) is 37% higher than the last 4 quarters average of 33.2 and 36% higher than the 5-year quarterly average of 33.5
The stock's price to book (P/B) is 36% less than its 5-year quarterly average of 7.5 but 7% more than its last 4 quarters average of 4.5
The P/S is 22% below the 5-year quarterly average of 10.1
EW's revenue is up by 14% year-on-year and by 3.9% since the previous quarter

Efficiency

How efficient is Edwards Lifesciences business performance
EW's return on assets has dropped by 76% year-on-year but it is up by 2.5% since the previous quarter
Edwards Lifesciences's return on equity has shrunk by 76% YoY
The company's return on sales has shrunk by 73% YoY
The company's return on invested capital has shrunk by 73% YoY

Dividends

What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EW.

Financial health

How did Edwards Lifesciences financials performed over time
The company's current ratio rose by 19% QoQ
EW's quick ratio is up by 17% since the previous quarter
The debt is 93% less than the equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.